71420-92-3

Usage

Uses

Used in Pharmaceutical Synthesis:
4-BOC-AMINOMETHYLPHENYLACETIC ACID is used as a key intermediate in the synthesis of glycine-site N-methyl-D-aspartate (NMDA) antagonists. These antagonists possess anticonvulsant activities and are crucial in the development of treatments for epilepsy and other seizure disorders. 4-BOC-AMINOMETHYLPHENYLACETIC ACID's unique structure allows for the creation of molecules that can effectively target and modulate the NMDA receptor, providing a promising avenue for the development of novel therapeutic agents.
Used in Inhibitor Development:
In the field of enzyme inhibition, 4-BOC-AMINOMETHYLPHENYLACETIC ACID is utilized to prepare potent dipeptide inhibitors of the pp60c-src SH2 domain. The pp60c-src is a non-receptor tyrosine kinase that plays a significant role in various cellular processes, including cell growth, differentiation, and transformation. Inhibiting the pp60c-src SH2 domain can help regulate these processes and potentially lead to the development of treatments for various diseases, such as cancer.
Used in Chemical Research:
Due to its unique chemical properties and structure, 4-BOC-AMINOMETHYLPHENYLACETIC ACID is also used in chemical research as a building block for the synthesis of various organic compounds. Researchers can use 4-BOC-AMINOMETHYLPHENYLACETIC ACID to explore new reaction pathways, develop novel synthetic methods, and create innovative molecules with potential applications in various industries, including pharmaceuticals, materials science, and agrochemicals.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 1200-05-1 2-(4-(aminomethyl)phenyl)acetic acid 
• 205237-12-3 (4-Azidomethyl-phenyl)-acetic acid benzyl ester 
• 191871-32-6 [4-(tert-butoxycarbonylamino-methyl)-phenyl]-acetic acid methyl ester 
• 52798-01-3 methyl 4-cyanobenzeneacetate 
• 41841-16-1 (4-bromo-phenyl)-acetic acid methyl ester 
• 444807-46-9 2-(4-(aminomethyl)phenyl)acetic acid methyl ester 
• 1878-68-8 2-(4-bromophenyl)-acetic acid 
• 13737-36-5 4-bromophenylacetic acid 
• 119549-47-2 2-(4-(bromomethyl)phenyl)acetyl chloride 
• 140233-65-4 (4-bromomethylphenyl)acetic acid benzyl ester 
• 42383-05-1 2-(4-(aminomethyl)phenyl)acetic acid hydrochloride 
• 34619-03-9 tert-butyldicarbonate 
• 5462-71-5 4-cyanophenylacetic acid 

Downstream Products

• 205236-64-2 (S)-4-{(S)-2-{2-[4-(tert-Butoxycarbonylamino-methyl)-phenyl]-acetylamino}-3-[4-(di-tert-butoxy-phosphoryloxy)-phenyl]-propionylamino}-4-dipentylcarbamoyl-butyric acid tert-butyl ester 
• 330595-62-5 1,4-bis-(4-N-tert-butoxycarbonylaminomethylbenzylcarbonyl-1-aminoprop-2-ynyl)-benzene 
• 330595-63-6 1,2-bis-(4-N-tert-butoxycarbonylaminomethylbenzylcarbonyl-1-aminoprop-2-ynyl)-benzene 
• 928649-33-6 N-(tert-butoxycarbonyl)-4-(iso-propylcarbamoyl-methyl)-benzylamine 
• 1257585-80-0 C₁₄H₂₀N₂O₃ 
• 1257585-81-1 C₉H₁₂N₂O*ClH 
• 1257585-82-2 C₁₆H₁₆N₂O₄S 
• 1257585-83-3 C₁₅H₁₆N₄O₃S 
• 1200-05-1 2-(4-(aminomethyl)phenyl)acetic acid 
• 1610413-97-2 C₃₄H₅₄N₄O₁₀ 
• 1610414-00-0 C₃₃H₄₅N₇O₁₇S 

Relevant academic research and scientific papers

HETEROARYL-CARBOXYLIC ACIDS AS HISTONE DEMETHYLASE INHIBITORS

The invention relates to heteroaryl-carboxylic acids as described herein, useful as histone demethylase inhibitors. The invention also relates to pharmaceutical compositions comprising these compounds and to their use in therapy, including e.g., in the treatment of cancer.

COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES AS GLUTAMINASE INHIBITORS FOR TREATING CANCERS THEREOF

Provided are compounds of formula (I), wherein X, Y, Z, W, m, n, o, p, R1, R2 and R6 are defined as in the description. Pharmaceutical compositions and uses as glutaminase inhibitors for treating cancers thereof are also provided.

HETEROCYCLIC COMPOUND AND HEMATOPOIETIC STEM CELL AMPLIFIER

An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy useful for treatment of various disorders is provided. An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells containing a compound represented by the formula (I) (wherein X, Y, Z, Ar1, R1, R2, R3, R4, R5, R6 and R7 are as defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof, which can expand hematopoietic stem cells and/or hematopoietic progenitor cells.

6-ARYLALKYLAMINO- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS

The present invention provides 6-substituted 2,3,4,5-tetrahydro-lH- benzo[d]azepines of Formula (I) as selective 5-HT2c receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety, where, R6 is -NR10R11, where R10 is substituted phenylalkyl or substituted pyridylalkyl and other substituents are as defined in the specification.

4,6-DISUBSTITUTED PYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS

The invention relates to novel pyrimidine derivatives of Formula (I), which are efficacious inhibitors of protein kinases, in particular of one or more isoforms of the protein kinase B/Akt.

Arylacetamide κ opioid receptor agonists with reduced cytochrome P450 2D6 inhibitory activity

Some κ opioid receptor agonists of the arylacetamide class, for example, ICI 199441 (1), were found to strongly inhibit the activity of cytochrome P450 2D6 (CYP2D6) (1: CYP2D6 IC50 = 26 nM). Certain analogs bearing a substituted sulfonylamino group, for example, 13, were discovered to have significantly reduced CYP2D6 inhibitory activity (13: CYP2D6 IC50 > 10 μM) while displaying high affinity toward the cloned human κ opioid receptor, good κ/δ and κ/μ selectivity, and potent in vitro and in vivo agonist activity.

Sulfonylamino phenylacetamide derivatives and methods of their use

Sulfonylamino phenylacetamide derivatives of the general formula are disclosed. Pharmaceutical compositions containing the compounds and methods for their use are also disclosed. In certain embodiments, the compounds of the invention that, preferably: (1) bind with high affinity to κ opioid receptors; (2) display good opioid receptor selectivity of κ versus μ and κ versus δ; and (3) do not substantially inhibit cytochrome P450 enzymatic activity, in particular CYP2D6, CYP2C9 and CYP3A4.

Potent dipeptide inhibitors of the pp60(c-src) SH2 domain

The design, synthesis, and evaluation of dipeptide analogues as ligands for the pp60(c-src) SH2 domain are described. The critical binding interactions between Ac-Tyr-Glu-N(n-C5H11)2 (2) and the protein are established and

Effect of Conformational Mobility and Hydrogen-Bonding Interactions on the Selectivity of Some Guanidinoaryl-Substituted Mechanism-Based Inhibitors of Trypsin-like Serine Proteases

Previously, we had reported that some guanidino-substituted α- and β-aryl enol lactones I and II behaved as selective, mechanism-based inhibitors of some trypsin-like proteases (Rai, R.; Katzenellenbogen.J.A.J.Med.Chem., submitted).In this study, we describe the synthesis and kinetic evaluation of some related, guanidino-substituted enol lactones having greater conformational mobility and affording additional hydrogen-bonding sites at the active site.The α-aryl-substituted lactones 1 and 2, which have greater conformational mobility in the guanidinoaryl linkage than I, selectively inhibited the trypsin-like enzymes, and they were relatively poor inactivators of α-chymotrypsin and human neutrophil elastase (HNE).The iodo enol lactone 2 permanently inactivated trypsin, urokinase, tissue plasminogen activator, and plasmin, showing exceptionally high specificity in its interaction with trypsin and urokinase.The selectivity pattern exhibited by the closely related, conformationally less mobile α-aryl-substituted iodo lactone Ib, which was previously shown to be a selective suicide substrate of urokinase and plasmin, provides an interesting comparison.The α-benzamido-substituted lactones 3 and 4, which afford an additional site for active-site hydrogen bonding, were found to be very potent alternate substrate inhibitors of trypsin and urokinase.In addition, the iodo lactone 4 permanently inactivated α-chymotropsin.The importance of secondary interactions in increasing the specificities in the case of α-chymotrypsin is discussed.